PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24595197-0	2014	Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer"s disease.	Carnitine	40-51	apolipoprotein E	Homo sapiens	59-76	
24595197-7	2014	Our results suggest APOE genotype-dependent differences in L-carnitine synthesis or metabolism along AD, and insinuate that L-carnitine treatments would be more beneficial for AD patients not carrying the APOE4 isoform.	Carnitine	124-135	apolipoprotein E	Homo sapiens	20-24	
24595197-7	2014	Our results suggest APOE genotype-dependent differences in L-carnitine synthesis or metabolism along AD, and insinuate that L-carnitine treatments would be more beneficial for AD patients not carrying the APOE4 isoform.	Carnitine	124-135	apolipoprotein E	Homo sapiens	205-210	
33991295-7	2021	Using analysis of variance, the monoacylglycerol factor, cholesterol ester factor, the factor for triacylglycerols that consist mostly of polyunsaturated fatty acids, sphingosine, and free carnitine significantly differed by APOE (p < 0.05, false discovery rate < 0.30).	Carnitine	189-198	apolipoprotein E	Homo sapiens	225-229	
24595197-5	2014	We found that non-APOE4 carriers show lower levels of L-carnitine in CSF early in AD.	Carnitine	54-65	apolipoprotein E	Homo sapiens	18-23	
24595197-7	2014	Our results suggest APOE genotype-dependent differences in L-carnitine synthesis or metabolism along AD, and insinuate that L-carnitine treatments would be more beneficial for AD patients not carrying the APOE4 isoform.	Carnitine	59-70	apolipoprotein E	Homo sapiens	20-24